GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (NAS:ADAP) » Definitions » Future 3-5Y Total Revenue Growth Rate

ADAP (Adaptimmune Therapeutics) Future 3-5Y Total Revenue Growth Rate : N/A (As of Jul. 23, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Adaptimmune Therapeutics Future 3-5Y Total Revenue Growth Rate?

Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Adaptimmune Therapeutics's Future 3-5Y Total Revenue Growth Rate is N/A.

Competitive Comparison of Adaptimmune Therapeutics's Future 3-5Y Total Revenue Growth Rate

For the Biotechnology subindustry, Adaptimmune Therapeutics's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptimmune Therapeutics's Future 3-5Y Total Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's Future 3-5Y Total Revenue Growth Rate falls into.


;
;

Adaptimmune Therapeutics  (NAS:ADAP) Future 3-5Y Total Revenue Growth Rate Explanation

Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Adaptimmune Therapeutics Future 3-5Y Total Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Adaptimmune Therapeutics's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptimmune Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (NAS:ADAP) » Definitions » Future 3-5Y Total Revenue Growth Rate
Comparable Companies
PDSB STRO ANRO IKNA MNOV AURX SER CLSD ZURA NRXP VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
473A:Germany
Address
60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Website
https://www.adaptimmune.com
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
Executives
Elliot Norry officer: Chief Medical Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Bertrand William C Jr officer: Chief Operating Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
John Lunger officer: Chief Patient Supply Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Adrian Rawcliffe officer: Chief Financial Officer 440 SOUTH BROAD STREET, UNIT 1906, PHILADELPHIA PA 19146
Cintia Piccina officer: Chief Commercial Officer 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R
Kristen Hege director 500 FORBES BLVD, SOUTH SAN FRANCISCO CA 94070
Garry E Menzel director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Priti Hegde director TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Andrew R Allen director 2525 28TH STREET, SUITE 200, BOULDER CO 80301
Gavin Wood officer: Chief Financial Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Joanna Elizabeth Brewer officer: Chief Scientific Officer 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Helena Katrina Tayton-martin officer: Chief Operating Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Lawrence M Alleva director 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
James Noble director, officer: Chief Executive Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX